Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AXGN

AXGN - AxoGen Inc Stock Price, Fair Value and News

10.69USD+0.13 (+1.23%)Market Closed
Watchlist

Market Summary

USD10.69+0.13
Market Closed
1.23%

AXGN Stock Price

View Fullscreen

AXGN RSI Chart

AXGN Valuation

Market Cap

460.1M

Price/Earnings (Trailing)

-19.8

Price/Sales (Trailing)

3.02

EV/EBITDA

-42.18

Price/Free Cashflow

-19.86

AXGN Price/Sales (Trailing)

AXGN Profitability

EBT Margin

-9.56%

Return on Equity

-23.76%

Return on Assets

-11.94%

Free Cashflow Yield

-5.04%

AXGN Fundamentals

AXGN Revenue

Revenue (TTM)

152.3M

Rev. Growth (Yr)

11.67%

Rev. Growth (Qtr)

8.17%

AXGN Earnings

Earnings (TTM)

-23.2M

Earnings Growth (Yr)

5.3%

Earnings Growth (Qtr)

38.6%

Breaking Down AXGN Revenue

Last 7 days

7.3%

Last 30 days

34.2%

Last 90 days

80.3%

Trailing 12 Months

16.9%

How does AXGN drawdown profile look like?

AXGN Financial Health

Current Ratio

3.28

Debt/Equity

0.47

Debt/Cashflow

-0.09

AXGN Investor Care

Shares Dilution (1Y)

1.79%

Diluted EPS (TTM)

-0.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023144.2M147.9M152.3M0
2022127.3M128.2M134.0M138.6M
2021119.1M130.5M128.3M127.4M
2020107.7M103.1M108.0M112.3M
201990.0M96.1M102.0M106.7M
201865.4M70.9M77.5M83.9M
201745.2M50.0M54.9M60.4M
201630.5M34.5M37.5M41.1M
201518.6M20.8M24.3M27.3M
201411.9M13.3M15.0M16.8M
20138.2M9.0M10.0M10.9M
20125.4M6.2M7.0M7.7M
20113.5M3.9M4.4M4.8M
20100003.0M

Tracking the Latest Insider Buys and Sells of AxoGen Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 01, 2024
naor nir
acquired
-
-
300,000
cfo
Dec 11, 2023
mariani peter j
sold
-93,809
7.50475
-12,500
evp & chief financial officer
Oct 13, 2023
devinney erick wayne
back to issuer
-3,490
4.04
-864
vp peripheral nerve science
Oct 13, 2023
mariani peter j
back to issuer
-13,182
4.04
-3,263
evp & chief financial officer
Oct 13, 2023
scopelianos angelo
back to issuer
-5,668
4.04
-1,403
chief r&d officer
Oct 13, 2023
donovan michael patrick
back to issuer
-5,668
4.04
-1,403
vp operations
Oct 13, 2023
martinez maria d.
back to issuer
-5,668
4.04
-1,403
chief human resources officer
Sep 06, 2023
wendell amy mcbride
bought
62,240
6.224
10,000
-
Aug 24, 2023
burke william p. mr.
acquired
37,860
6.31
6,000
-
Aug 23, 2023
burke william p. mr.
bought
65,600
6.56
10,000
-

1–10 of 50

Which funds bought or sold AXGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
36,578
138,048
-%
Feb 26, 2024
PERCEPTIVE ADVISORS LLC
reduced
-7.71
1,141,740
5,521,240
0.12%
Feb 20, 2024
Quarry LP
reduced
-71.78
-10,813
6,782
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-12.22
31,000
188,000
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
new
-
427,000
427,000
0.04%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
516,580
516,580
-%
Feb 15, 2024
Empire Financial Management Company, LLC
added
17.25
180,490
480,490
0.19%
Feb 15, 2024
State of Wyoming
new
-
155,656
155,656
0.03%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
615
615
-%
Feb 15, 2024
Legal & General Group Plc
reduced
-43.78
-214,852
711,078
-%

1–10 of 47

Are Funds Buying or Selling AXGN?

Are funds buying AXGN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AXGN
No. of Funds

Unveiling AxoGen Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
arrowmark colorado holdings llc
11.97%
5,152,300
SC 13G/A
Feb 13, 2024
vanguard group inc
5.73%
2,465,496
SC 13G
Feb 12, 2024
morgan stanley
6.6%
2,859,421
SC 13G
Feb 02, 2024
soleus capital master fund, l.p.
6.0%
2,595,815
SC 13G/A
Jan 26, 2024
blackrock inc.
7.8%
3,342,773
SC 13G/A
Aug 11, 2023
soleus capital master fund, l.p.
8.2%
3,541,298
SC 13G
Aug 10, 2023
arrowmark colorado holdings llc
10.34%
4,431,629
SC 13G/A
Feb 14, 2023
point72 asset management, l.p.
4.3%
1,815,000
SC 13G/A
Feb 03, 2023
first light asset management, llc
4.59%
1,942,270
SC 13G
Jan 31, 2023
blackrock inc.
7.5%
3,159,410
SC 13G/A

Recent SEC filings of AxoGen Inc

View All Filings
Date Filed Form Type Document
Feb 23, 2024
4
Insider Trading
Feb 23, 2024
4
Insider Trading
Feb 23, 2024
4
Insider Trading
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G
Major Ownership Report
Feb 12, 2024
SC 13G
Major Ownership Report
Feb 06, 2024
144
Notice of Insider Sale Intent
Feb 02, 2024
SC 13G/A
Major Ownership Report
Jan 26, 2024
SC 13G/A
Major Ownership Report
Jan 11, 2024
3
Insider Trading

What is the Fair Value of AXGN?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to AxoGen Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
206.4B
40.1B
0.08% 5.41%
36.07
5.15
-8.12% -17.45%
68.0B
19.5B
1.90% -2.48%
54.13
3.49
4.02% -22.04%
22.5B
3.9B
13.67% -2.23%
50.61
5.83
3.42% 23.09%
20.8B
14.9B
3.05% 1.38%
7.84
1.39
2.01% 209.17%
MID-CAP
9.9B
12.3B
2.56% -12.12%
23.75
0.8
-2.44% -22.68%
9.8B
2.7B
6.89% -27.73%
-15.3
3.65
-4.68% 82.43%
9.3B
3.5B
8.76% 25.90%
32.56
2.66
4.97% 18.89%
6.9B
4.0B
-8.15% -6.44%
-51.28
1.74
1.10% 85.84%
3.5B
366.4M
-1.40% 20.18%
-567.84
9.44
33.86% 89.80%
2.4B
6.6B
-4.32% -4.67%
12.53
0.37
2.78% -0.99%
SMALL-CAP
1.4B
3.2B
8.08% -63.68%
-2.06
0.44
7.73% -1066.14%
369.2M
163.3M
8.18% -20.52%
-15.03
2.26
7.14% -56.09%
218.4M
329.5M
3.17% -52.24%
-15.47
0.66
0.49% 64.22%
73.4M
50.3M
4.50% -30.54%
-4.85
1.46
3.23% 20.81%
4.6M
3.7M
-15.66% 215.09%
-0.37
1.22
5.77% 8.23%

AxoGen Inc News

Latest updates
AmericanBankingNEWS38 hours ago
MarketBeat27 Feb 202408:52 am
Yahoo Finance UK26 Feb 202402:15 pm
Yahoo Finance06 Feb 202408:00 am
Seeking Alpha04 Jan 202408:00 am

AxoGen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue8.2%41,271,00038,155,00036,664,00036,164,00036,959,00034,454,00031,007,00031,537,00031,204,00033,580,00031,037,00032,495,00033,428,00022,116,00024,261,00028,162,00028,564,00026,701,00023,285,00023,433,00022,660,000
Gross Profit7.4%33,228,00030,927,00029,955,00030,023,00030,783,00028,170,00025,461,00026,109,00025,965,00026,488,00025,865,00027,032,00027,731,00016,511,00019,445,00023,281,00024,054,00022,457,00019,571,00019,793,00019,196,000
Costs and Expenses-1.5%37,253,00037,829,00037,296,00035,631,00035,638,00036,094,00036,781,00031,462,00032,654,00033,642,00032,085,00032,406,00028,776,00024,765,00027,954,00030,700,00030,166,00030,129,00029,774,00025,647,50024,031,000
  S&GA Expenses2.8%21,429,00020,838,00021,618,00019,879,00019,792,00019,669,00020,888,00017,734,50018,370,00019,250,00017,973,00019,805,00017,726,00014,290,00017,838,00018,804,00018,245,00018,467,00016,434,00015,468,50014,653,000
  R&D Expenses-5.1%6,989,0007,363,0006,679,0006,811,0007,050,0007,022,0006,275,0006,302,0006,404,0005,723,0005,748,0004,931,0004,230,0004,071,0004,614,0004,912,0004,181,0004,282,0004,139,0003,806,5003,307,000
EBITDA Margin12.6%-0.07-0.08-0.08-0.08-0.08-0.08-0.08-0.08-0.08-0.08-0.09-0.11---------
Interest Expenses458.8%827,000148,00016,000-40,00061,000249,000354,000-70,500417,000565,000444,000595,000397,00031,00031,0009,0006,00011,00014,000-114,000192,000
EBT Margin2.8%-0.10-0.10-0.10-0.11-0.11-0.11-0.11-0.11-0.11-0.11-0.12-0.13---------
Net Income38.6%-4,089,000-6,660,000-7,074,000-5,415,000-4,318,000-7,740,000-11,475,000-5,286,000-7,141,000-7,898,000-6,660,000-6,010,000-1,479,000-8,105,000-8,192,000-7,038,000-5,571,000-7,022,000-9,504,000-5,224,000-4,102,000
Net Income Margin3.8%-0.15-0.16-0.17-0.21-0.22-0.25-0.25-0.21-0.22-0.17-0.19-0.21---------
Free Cashflow49.9%-2,064,000-4,123,000-11,727,000-5,260,000-5,059,000-9,737,000-16,088,000-8,684,000-10,093,000-8,524,000-13,915,000-161,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets1.6%195192189195196196198208210211197201194170145155154157160160162
  Current Assets1.5%87.0086.0089.0098.00102107112127135142135145140140120135137141146151153
    Cash Equivalents33.9%31.0023.008.0015.0021.0018.0021.0039.0053.0059.0046.0056.0068.0086.0042.0042.0031.0031.0030.0030.0026.00
  Inventory8.4%23.0021.0020.0019.0019.0019.0017.0017.0015.0013.0013.0013.0012.0013.0015.0014.0014.0014.0013.0012.0011.00
  Net PPE--------63.0056.0051.0044.0038.0036.0025.0020.0015.0012.0010.009.008.008.00
Liabilities2.5%97.0094.0092.0094.0094.0094.0094.0095.0095.0092.0078.0078.0072.0050.0021.0022.0019.0019.0020.0013.0012.00
  Current Liabilities11.3%27.0024.0021.0024.0024.0024.0023.0024.0023.0022.0022.0023.0019.0014.0019.0021.0017.0016.0016.0013.0012.00
  Long Term Debt0.5%46.0046.0046.0046.0045.0045.0045.0045.0046.0046.0032.0032.0032.0032.001.00-2.002.003.000.000.00
    LT Debt, Current-------------2.002.002.002.002.002.001.000.000.00
    LT Debt, Non Current0.5%46.0046.0046.0046.0045.0045.0045.0045.0046.0046.0032.0032.0019.00-1.00-2.002.003.000.000.00
Shareholder's Equity0.7%98.0097.0098.00101101102104113115119120123122120124132135138141147149
  Retained Earnings-1.5%-277-273-266-259-254-249-242-230-225-218-210-203-197-196-188-179-172-167-160-150-145
  Additional Paid-In Capital1.3%375370364360355351346343340336330326319316312312308305301297295
Shares Outstanding0.1%43.0043.0043.0042.0042.0042.0042.0042.0041.0041.0041.0040.00---------
Float------222---642---217---540---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations456.8%1,626292-7,4231,362-689-5,688-11,051-1,514-376-695-10,8202,8372,618-7,029-8,052-3,330-1,864-5,811-8,867-4,976-2,966
  Share Based Compensation-11.9%4,7475,3902,9544,1543,8494,9102,6781,5092,9113,8052,6942,7452,9472,2225562,9202,3952,6742,3151,6252,211
Cashflow From Investing-58.1%5,99414,322-786-1,2092,9712,279-7,241-13,585-6,777-4,157870-19,352-21,13014,9698,55013,5869214,9947,7708,544-105,823
Cashflow From Financing-99.4%5.0089863381321567195.001,04380518,0875174,51519136,096-3289136202,1733251,097856
  Buy Backs------------6.008.0017.00639------

AXGN Income Statement

2023-09-30
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Revenues$ 41,271$ 36,959$ 116,090$ 102,420
Cost of goods sold8,0436,17621,98018,006
Gross profit33,22830,78394,11084,414
Costs and expenses:    
Sales and marketing21,42919,79263,88560,349
Research and development6,9897,05021,03220,347
General and administrative8,8358,79627,46127,817
Total costs and expenses37,25335,638112,378108,513
Loss from operations(4,025)(4,855)(18,268)(24,099)
Other income (expense):    
Investment income3671861,151172
Interest expense(827)(61)(992)(664)
Change in fair value of derivatives4024696491,155
Other expense(6)(57)(363)(97)
Total other (expense) income, net(64)537445566
Net loss$ (4,089)$ (4,318)$ (17,823)$ (23,533)
Weighted average common shares outstanding - basic (in shares)43,022,32842,220,51942,821,28442,008,013
Weighted average common shares outstanding - diluted (in shares)43,022,32842,220,51942,821,28442,008,013
Loss per common share - basic (in USD per share)$ (0.10)$ (0.10)$ (0.42)$ (0.56)
Loss per common share - diluted (in USD per share)$ (0.10)$ (0.10)$ (0.42)$ (0.56)

AXGN Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 31,094$ 15,284
Restricted cash6,0026,251
Investments1,49433,505
Accounts receivable, net of allowance for doubtful accounts of $319 and $650, respectively23,26322,186
Inventory23,01918,905
Prepaid expenses and other2,5671,944
Total current assets87,43998,075
Property and equipment, net89,03079,294
Operating lease right-of-use assets13,87314,369
Intangible assets, net4,2883,649
Total assets194,630195,387
Current liabilities:  
Accounts payable and accrued expenses25,55022,443
Current maturities of long-term lease obligations1,0961,310
Total current liabilities26,64623,753
Long-term debt, net of debt discount and financing fees46,37845,712
Long-term lease obligations19,92720,405
Debt derivative liabilities3,8694,518
Total liabilities96,82094,388
Commitments and contingencies
Shareholders’ equity:  
Common stock, 0.01 par value per share; 100,000,000 shares authorized; 43,039,399 and 42,445,517 shares issued and outstanding430424
Additional paid-in capital374,783360,155
Accumulated deficit(277,403)(259,580)
Total shareholders’ equity97,810100,999
Total liabilities and shareholders’ equity$ 194,630$ 195,387
AXGN
AxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
 CEO
 WEBSITEwww.axogeninc.com
 EMPLOYEES394

AxoGen Inc Frequently Asked Questions


What is the ticker symbol for AxoGen Inc? What does AXGN stand for in stocks?

AXGN is the stock ticker symbol of AxoGen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AxoGen Inc (AXGN)?

As of Thu Feb 29 2024, market cap of AxoGen Inc is 454.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXGN stock?

You can check AXGN's fair value in chart for subscribers.

What is the fair value of AXGN stock?

You can check AXGN's fair value in chart for subscribers. The fair value of AxoGen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AxoGen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AXGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AxoGen Inc a good stock to buy?

The fair value guage provides a quick view whether AXGN is over valued or under valued. Whether AxoGen Inc is cheap or expensive depends on the assumptions which impact AxoGen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXGN.

What is AxoGen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 29 2024, AXGN's PE ratio (Price to Earnings) is -19.56 and Price to Sales (PS) ratio is 2.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AxoGen Inc's stock?

In the past 10 years, AxoGen Inc has provided 0.093 (multiply by 100 for percentage) rate of return.